Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)

About Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IRWD
  • CUSIP: 46333X10
  • Web: www.ironwoodpharma.com
Capitalization:
  • Market Cap: $2.32 billion
  • Outstanding Shares: 149,591,000
Average Prices:
  • 50 Day Moving Avg: $15.49
  • 200 Day Moving Avg: $17.03
  • 52 Week Range: $12.48 - $19.94
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -29.28
  • P/E Growth: -0.25
Sales & Book Value:
  • Annual Revenue: $270.81 million
  • Price / Sales: 8.57
  • Book Value: $0.03 per share
  • Price / Book: 517.33
Profitability:
  • EBIDTA: ($84,770,000.00)
  • Net Margins: -52.97%
  • Return on Equity: -333.83%
  • Return on Assets: -18.83%
Debt:
  • Debt-to-Equity Ratio: 79.64%
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
Misc:
  • Average Volume: 1.22 million shs.
  • Beta: 1.48
  • Short Ratio: 11.15
 

Frequently Asked Questions for Ironwood Pharmaceuticals (NASDAQ:IRWD)

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.05. The firm earned $65.10 million during the quarter, compared to analyst estimates of $70 million. Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The business's revenue was up 19.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.16) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

When will Ironwood Pharmaceuticals make its next earnings announcement?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Ironwood Pharmaceuticals.

Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2017?

9 brokers have issued 1 year price objectives for Ironwood Pharmaceuticals' stock. Their forecasts range from $13.00 to $21.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $18.13 in the next year. View Analyst Ratings for Ironwood Pharmaceuticals.

Are investors shorting Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 16,348,161 shares, an increase of 16.0% from the July 31st total of 14,098,775 shares. Based on an average trading volume of 1,492,918 shares, the short-interest ratio is currently 11.0 days. Approximately 12.3% of the shares of the company are sold short.

Who are some of Ironwood Pharmaceuticals' key competitors?

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:

  • Peter M. Hecht Ph.D., Chief Executive Officer, Director
  • Thomas Graney, Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
  • Mark G. Currie Ph.D., Senior Vice President, Chief Scientific Officer, President - Research and Development
  • Thomas A. McCourt, Senior Vice President - Marketing and Sales, Chief Commercial Officer
  • Halley E. Gilbert Esq., Senior Vice President, Chief Legal Officer, Secretary
  • Christopher I. Wright M.D. Ph.D., Senior Vice President - Global Development and Chief Development Officer
  • Terrance G. McGuire, Non-Executive Independent Chairman of the Board
  • Andrew Dreyfus, Independent Director
  • Marsha H. Fanucci, Independent Director
  • Julie H. McHugh, Independent Director

Who owns Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (12.59%), Vanguard Group Inc. (7.24%), Janus Henderson Group PLC (5.90%), State Street Corp (3.35%), EcoR1 Capital LLC (2.78%) and Pictet Asset Management Ltd. (1.28%). Company insiders that own Ironwood Pharmaceuticals stock include Edward P Owens, Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht, Thomas A Mccourt and Thomas Graney. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Who sold Ironwood Pharmaceuticals stock? Who is selling Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Spark Investment Management LLC, Goldman Sachs Group Inc., Blue Jay Capital Management LLC, Gotham Asset Management LLC, Artal Group S.A., Alliancebernstein L.P. and Bank of Montreal Can. Company insiders that have sold Ironwood Pharmaceuticals stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Who bought Ironwood Pharmaceuticals stock? Who is buying Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, EcoR1 Capital LLC, Penn Capital Management Co. Inc., State Street Corp, State of Wisconsin Investment Board, New York State Common Retirement Fund, Pictet Asset Management Ltd. and Vanguard Group Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy Ironwood Pharmaceuticals stock?

Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $15.52.


MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $18.13 (16.78% upside)

Analysts' Ratings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/25/2017MizuhoReiterated RatingBuy$23.00 -> $20.00MediumView Rating Details
8/21/2017Cowen and CompanySet Price TargetBuy$20.00MediumView Rating Details
7/22/2017Wells Fargo & CompanySet Price TargetBuy$19.00LowView Rating Details
7/21/2017Wood & CompanyDowngradeOverweight -> NeutralLowView Rating Details
7/21/2017J P Morgan Chase & CoReiterated RatingOverweight -> Neutral$20.00 -> $19.00HighView Rating Details
6/16/2017WedbushReiterated RatingNeutral$13.00LowView Rating Details
3/13/2017BTIG ResearchReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
2/22/2017Barclays PLCReiterated RatingEqual Weight -> Equal Weight$13.00 -> $16.00N/AView Rating Details
9/27/2016WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingMarket Perform$10.00 -> $14.00N/AView Rating Details
4/28/2016JP Morgan CazenoveReiterated RatingOverweight$15.00N/AView Rating Details
4/26/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
3/21/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$14.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Earnings by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Earnings History by Quarter for Ironwood Pharmaceuticals (NASDAQ IRWD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017N/AView Earnings Details
8/3/2017Q2 2017($0.23)($0.28)$70.00 million$65.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.19)($0.33)$69.39 million$52.16 millionViewListenView Earnings Details
2/21/2017Q416($0.24)($0.12)$77.34 million$87.50 millionViewListenView Earnings Details
11/3/2016Q316($0.23)($0.18)$60.01 million$66.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.15)($0.16)$54.49 million$54.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details
4/29/2014Q1($0.45)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details
10/16/2012$0.17$0.42ViewN/AView Earnings Details
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)
2017 EPS Consensus Estimate: ($0.75)
2018 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.20)($0.22)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.21)($0.12)($0.17)
Q4 20172($0.19)($0.10)($0.15)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Ownership Percentage: 7.63%
Institutional Ownership Percentage: 97.90%
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Julie MchughDirectorSell1,500$16.16$24,240.00View SEC Filing  
8/18/2017Gina ConsylmanInsiderSell207$14.34$2,968.38View SEC Filing  
6/22/2017Halley E GilbertInsiderSell35,000$19.75$691,250.00View SEC Filing  
5/15/2017Thomas A MccourtInsiderSell30,000$18.20$546,000.00View SEC Filing  
2/14/2017Halley E GilbertInsiderSell37,385$16.75$626,198.75View SEC Filing  
1/12/2017Peter M HechtCEOSell65,987$15.67$1,034,016.29View SEC Filing  
12/5/2016Lawrence S OlanoffDirectorSell3,200$15.68$50,176.00View SEC Filing  
9/6/2016Lawrence S OlanoffDirectorSell3,200$13.72$43,904.00View SEC Filing  
8/19/2016Gina ConsylmanInsiderSell207$13.54$2,802.78View SEC Filing  
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.00View SEC Filing  
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.25View SEC Filing  
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.00View SEC Filing  
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.00View SEC Filing  
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00View SEC Filing  
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.00View SEC Filing  
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.62View SEC Filing  
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.50View SEC Filing  
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.00View SEC Filing  
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.25View SEC Filing  
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.00View SEC Filing  
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.00View SEC Filing  
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.00View SEC Filing  
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.13View SEC Filing  
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Latest Headlines for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : September 13, 2017
finance.yahoo.com - September 14 at 6:33 AM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 12 at 6:56 AM
feeds.benzinga.com logoTiGenix strengthens US operations with senior appointments
feeds.benzinga.com - September 12 at 1:34 AM
finance.yahoo.com logoIronwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 11 at 8:42 PM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Director Sells $24,240.00 in Stock
www.americanbankingnews.com - September 7 at 8:28 PM
streetinsider.com logoForm 8-K IRONWOOD PHARMACEUTICALS For: Sep 01
www.streetinsider.com - September 6 at 7:58 PM
finance.yahoo.com logoIronwood Pharmaceuticals Announces Leadership Change
finance.yahoo.com - September 6 at 7:58 PM
americanbankingnews.com logoContrasting Merrimack Pharmaceuticals (MACK) and Ironwood Pharmaceuticals (IRWD)
www.americanbankingnews.com - September 5 at 6:16 AM
americanbankingnews.com logo$68.04 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - September 5 at 3:00 AM
finance.yahoo.com logoWhy Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?
finance.yahoo.com - September 4 at 6:52 PM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - September 4 at 12:20 AM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - September 3 at 8:54 AM
finance.yahoo.com logoIronwood Pharmaceuticals to Present at Upcoming September Investor Conferences
finance.yahoo.com - August 31 at 8:00 PM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - August 26 at 8:32 PM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Short Interest Up 16.0% in August
www.americanbankingnews.com - August 26 at 1:20 AM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - August 25 at 7:50 PM
nasdaq.com logoInteresting IRWD Put And Call Options For October 20th
www.nasdaq.com - August 24 at 8:04 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Medtronic and Ironwood Pharmaceuticals
finance.yahoo.com - August 24 at 8:04 AM
nasdaq.com logoIronwood Pharma's Combination Gout Drug Gets FDA Approval
www.nasdaq.com - August 23 at 5:57 AM
finance.yahoo.com logoIronwood Pharma's Combination Gout Drug Gets FDA Approval
finance.yahoo.com - August 23 at 5:57 AM
finance.yahoo.com logoFDA approves Ironwood Pharma's gout drug
finance.yahoo.com - August 21 at 7:09 PM
finance.yahoo.com logoIronwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers
finance.yahoo.com - August 21 at 7:09 PM
finance.yahoo.com logoIronwood Pharma Muted Despite FDA Approval
finance.yahoo.com - August 21 at 7:09 PM
finance.yahoo.com logoIronwood gets FDA approval for new drug for gout
finance.yahoo.com - August 21 at 7:09 PM
americanbankingnews.com logoCowen and Company Analysts Give Ironwood Pharmaceuticals, Inc. (IRWD) a $20.00 Price Target
www.americanbankingnews.com - August 21 at 6:02 PM
prnewswire.com logoGeneric Drugs Stock Performance Review -- Patheon, Zoetis, Ironwood Pharma, and Medicines Co.
www.prnewswire.com - August 21 at 8:52 AM
streetinsider.com logoIronwood Pharma (IRWD) Announces FDA Approval of DUZALLO for Treatment of Hyperuricemia in Patients with Uncontrolled Gout
www.streetinsider.com - August 21 at 8:52 AM
finance.yahoo.com logoIronwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout
finance.yahoo.com - August 21 at 8:52 AM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 18 at 6:40 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
finance.yahoo.com - August 12 at 12:21 AM
americanbankingnews.com logoFY2021 EPS Estimates for Ironwood Pharmaceuticals, Inc. Reduced by Analyst (IRWD)
www.americanbankingnews.com - August 7 at 10:22 AM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Given a $20.00 Price Target by Cowen and Company Analysts
www.americanbankingnews.com - August 5 at 9:56 PM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - August 5 at 8:22 PM
finance.yahoo.com logoEdited Transcript of IRWD earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 8:13 PM
finance.yahoo.com logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 1:08 AM
finance.yahoo.com logoIronwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : August 4, 2017
finance.yahoo.com - August 4 at 1:08 AM
finance.yahoo.com logoIronwood Pharmaceuticals Provides Second Quarter 2017 Investor Update
finance.yahoo.com - August 3 at 8:08 PM
finance.yahoo.com logoIronwood reports 2Q loss
finance.yahoo.com - August 3 at 8:08 PM
americanbankingnews.com logoMizuho Reiterates Buy Rating for Ironwood Pharmaceuticals, Inc. (IRWD)
www.americanbankingnews.com - August 2 at 8:22 PM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Cut to Sell at BidaskClub
www.americanbankingnews.com - July 31 at 4:29 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Quarterly Sales of $68.48 Million
www.americanbankingnews.com - July 31 at 8:18 AM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 9:18 AM
americanbankingnews.com logoWells Fargo & Company Analysts Give Ironwood Pharmaceuticals, Inc. (IRWD) a $19.00 Price Target
www.americanbankingnews.com - July 23 at 10:41 PM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Earns Outperform Rating from Cowen and Company
www.americanbankingnews.com - July 23 at 3:04 PM
americanbankingnews.com logoIronwood Pharmaceuticals, Inc. (IRWD) Given Buy Rating at Mizuho
www.americanbankingnews.com - July 23 at 3:04 PM
finance.yahoo.com logoIronwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease
finance.yahoo.com - July 22 at 10:15 PM
americanbankingnews.com logoJ P Morgan Chase & Co Reiterates "Neutral" Rating for Ironwood Pharmaceuticals, Inc. (IRWD)
www.americanbankingnews.com - July 22 at 2:53 PM
finance.yahoo.com logoIronwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : July 21, 2017
finance.yahoo.com - July 22 at 2:16 AM
finance.yahoo.com logoIronwood's Pipeline Needs Work, Analyst Downgrades
finance.yahoo.com - July 22 at 2:16 AM
finance.yahoo.com logoIronwood (IRWD) Reports Positive Data on Reflux Candidate
finance.yahoo.com - July 22 at 2:16 AM

Social

Chart

Ironwood Pharmaceuticals (IRWD) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff